Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and Neutropenia

2004920 citationsJournal Articlebronze Open Access

Authors

Thomas J. Walsh · National Institutes of Health

Hedy Teppler · Merck (France)

Gerald R. Donowitz · University of Virginia Health System

Johan Maertens · Universitair Ziekenhuis Leuven

Lindsey R. Baden · Brigham and Women's Hospital

Anna Dmoszyńska · 1 Military Clinical Hospital with Outpatient Clinic

Oliver A. Cornely

Abstract

Caspofungin is as effective as and generally better tolerated than liposomal amphotericin B when given as empirical antifungal therapy in patients with persistent fever and neutropenia.

Topics & Keywords

Antifungal resistance and susceptibility Fungal Infections and Studies Cystic Fibrosis Research Advances

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 351, Issue 14, pp. 1391-1402

DOI: 10.1056/nejmoa040446

Field-Weighted Citation Impact: 39.60